SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001811764-22-000082
Filing Date
2022-09-13
Accepted
2022-09-13 16:12:07
Documents
14
Period of Report
2022-09-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K pnt-20220913.htm   iXBRL 8-K 35386
2 EX-99.1 september132022-capitalrai.htm EX-99.1 15217
6 point-logoxcoloura.jpg GRAPHIC 17537
  Complete submission text file 0001811764-22-000082.txt   215095

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pnt-20220913.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pnt-20220913_lab.xml EX-101.LAB 23874
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pnt-20220913_pre.xml EX-101.PRE 12531
8 EXTRACTED XBRL INSTANCE DOCUMENT pnt-20220913_htm.xml XML 11209
Mailing Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268
Business Address 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 (317) 543-9957
POINT Biopharma Global Inc. (Filer) CIK: 0001811764 (see all company filings)

IRS No.: 850800493 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39373 | Film No.: 221240879
SIC: 2834 Pharmaceutical Preparations